高级搜索

卵巢癌铂耐药:PFI“二分法”的局限性与可能的改进

李笑宇, 张楠, 狄文

李笑宇, 张楠, 狄文. 卵巢癌铂耐药:PFI“二分法”的局限性与可能的改进[J]. 肿瘤防治研究, 2024, 51(10): 813-819. DOI: 10.3971/j.issn.1000-8578.2024.24.0677
引用本文: 李笑宇, 张楠, 狄文. 卵巢癌铂耐药:PFI“二分法”的局限性与可能的改进[J]. 肿瘤防治研究, 2024, 51(10): 813-819. DOI: 10.3971/j.issn.1000-8578.2024.24.0677
LI Xiaoyu, ZHANG Nan, DI Wen. Platinum Resistance in Ovarian Cancer: Limitations of PFI Binary Classification and Potential Improvements[J]. Cancer Research on Prevention and Treatment, 2024, 51(10): 813-819. DOI: 10.3971/j.issn.1000-8578.2024.24.0677
Citation: LI Xiaoyu, ZHANG Nan, DI Wen. Platinum Resistance in Ovarian Cancer: Limitations of PFI Binary Classification and Potential Improvements[J]. Cancer Research on Prevention and Treatment, 2024, 51(10): 813-819. DOI: 10.3971/j.issn.1000-8578.2024.24.0677

卵巢癌铂耐药:PFI“二分法”的局限性与可能的改进

详细信息
    作者简介:

    李笑宇(2001-),女,博士在读,主要从事妇产科临床与基础研究,ORCID: 0009-0002-7987-9320

    张楠(1989-),女,博士,主治医师,主要从事妇科肿瘤的基础和临床研究,ORCID: 0000-0002-8996-6105

    狄文: 上海交通大学医学院附属仁济医院主任医师,教授,博士生导师,上海市妇科肿瘤重点实验室主任,中国医师协会妇产科医师分会会长,中华医学会妇产科学分会副主任委员,上海市医师协会妇产科医师分会会长,上海市母婴安全专家委员会主任委员,《中华妇产科杂志》副总编,《中国实用妇科与产科杂志》和《上海医学》副主编以及多家杂志编委。担任国家卫生健康委员会住院医师规范化培训规划教材《妇产科学》、国家卫生和计划生育委员会“十三五”英文版规划教材全国高等学校教材《妇产科学》等多本教材主编。  获2010年教育部科技进步二等奖、2022年中华医学科技奖二等奖、2022年上海市科学技术奖一等奖、2018年上海医学科技奖一等奖、2009年上海医学奖二等奖及2009年上海科技进步三等奖。所编教材荣获2009年上海交通大学第十二届优秀教材特等奖、2011年上海市高校优秀教材二等奖、2015年上海普通高校优秀教材奖。2008年入选上海市科委优秀学科带头人培养计划、2011年入选上海市领军人物 。

    通讯作者:

    狄文(1960-),男,博士,主任医师,教授,主要从事妇产科临床与基础研究,E-mail: diwen163@163.com,ORCID: 0000-0003-4007-3856

    *并列第一作者

  • 中图分类号: R737.31

Platinum Resistance in Ovarian Cancer: Limitations of PFI Binary Classification and Potential Improvements

More Information
  • 摘要:

    卵巢癌是一种较为常见的妇科恶性肿瘤,临床上主要通过无铂间期将复发性卵巢癌分为铂耐药性与铂敏感性,分别对应不同的治疗方式及预后。铂耐药性卵巢癌的治疗十分困难,随着研究的深入,有学者提出根据无铂间期的“二分法”存在一定局限性。因此,本文将对复发性卵巢癌的分类、铂耐药性卵巢癌的治疗困境、无铂间期“二分法”的局限性与新的分类思路作一综述,帮助临床工作者更好地了解卵巢癌分类方面的研究进展,从而制定更加有效的治疗策略。

     

    Abstract:

    Ovarian cancer is a common gynecologic malignancy. In clinical practice, recurrent ovarian cancer is mainly classified into two categories on the basis of platinum-free interval, platinum-resistant and platinum-sensitive, corresponding to different treatment modalities and prognoses. The treatment of platinum-resistant ovarian cancer is challenging. Some scholars have pointed out limitations in the binary classification of platinum-free interval. In this article, the classification of recurrent ovarian cancer, the treatment challenges of platinum-resistant ovarian cancer, the limitations of the platinum-free interval binary classification, and new classification perspectives were reviewed to help physicians enhance their understanding on the research progress in ovarian cancer classification and develop more effective treatment strategies.

     

  • 鼻咽癌是最常见的头颈部肿瘤之一。我国为鼻咽癌高发地区,每年的发病率约为20/10万[1],由于鼻咽解剖结构及生物学行为的特殊性,很难行手术治疗,目前鼻咽癌公认和有效的治疗手段为放射治疗或以放疗为主的综合治疗。虽然放疗技术不断进步与放疗设备的不断更新,鼻咽癌的生存率有了较大的提高,但5年生存率仍为60%~80%[2],部分患者仍未能获得长期生存。TNM分期系统是鼻咽癌预后判断和指导治疗的重要依据,但临床发现同一分期患者即使接受相同的治疗方案,预后却不同[3-4],这提示鼻咽癌生物学差异的存在,仅基于解剖学信息的TNM临床分期系统还不能准确地预测鼻咽癌患者的预后。虽然EB病毒滴度、表皮生长因子受体、microRNA也可提示鼻咽癌的预后[5-7],但检测成本高,需要多中心合作,临床上可行性差。所以,亟需检测方便、价格低廉可预测鼻咽癌预后的标志物。

    流行病学研究证实,约25%的肿瘤由炎性反应发展而来,其与肿瘤的发生发展密切相关并且影响肿瘤患者的预后[8]。炎性反应指标,如白细胞计数[9]、血小板计数[10-11]、中性粒淋巴细胞比(neutrophil-lymphocyte ratio, NLR)[12-13]、血小板淋巴细胞比(platelet-lymphocyte ratio, PLR)[14-15]被发现可作为肿瘤的独立预后因素。这些血液指标检测方便,价格低廉,可广泛应用于临床,评估患者预后。本研究通过对91例鼻咽癌患者临床资料进行回顾性分析,评价治疗前PLR和NLR与鼻咽癌患者预后的相关性,为评估预后提供客观依据。

    回顾性收集2009年1月至2013年9月期间于西安交通大学第一附属医院和陕西省人民医院初治的91例鼻咽癌患者,所有病例均经病理证实。临床资料完整。排除标准:(1)合并有免疫性疾病以及其他恶性肿瘤的患者;(2)治疗前合并有急性或慢性感染;(3)合并有血液系统疾病、血栓或出血性疾病;(4)合并有严重的肝、肾疾病;(5)治疗前曾接受过放疗或化疗;(6)无远处转移。记录患者治疗前的中性粒细胞计数、淋巴细胞计数及血小板计数结果。

    入选患者采用3D-CRT或IMRT根治性放疗(有或无化疗),Ⅰ期患者仅接受单纯放射治疗,Ⅱ、Ⅲ、Ⅳ期患者接受以顺铂和5-氟尿嘧啶为主的辅助或同步放化疗。鼻咽原发灶和颈部转移淋巴结剂量为(70~76)Gy/(7~8)w/(35~38)f,颈部预防区域剂量为(50~60)Gy/(5~6)w/(25~30)f。根据患者的临床分期及不良反应给予2~6周期的全身化疗,化疗方案为:顺铂25 mg/m2,第1~3天静脉滴注;5-氟尿嘧啶500 mg/m2,第1~5天静脉滴注,每21天重复1周期。患者治疗结束后均定期随访,治疗后前2年,每3月检查一次,2年后半年复查一次,5年后1年复查1次。随访截止时间为2016年9月。

    采用SPSS19.0软件对数据进行统计学分析。绘制ROC曲线确定PLR和NLR与总生存期(overall survival, OS)及无进展生存期(progression-free survival, PFS)的相关性,选取截断值。应用Kaplan-Meier法进行生存分析并采用Log rank检验来检验。采用Cox比例风险回归模型分析多种因素对生存时间的影响。以P < 0.05为差异有统计学意义。

    91例患者的基本特征资料见表 1,中位年龄53岁(12~72)岁,女30例,男61例,男女比例2:1,Ⅰ、Ⅱ、Ⅲ、Ⅳ期患者分别为2、27、42、20例。单纯放疗患者9例,82例患者接受辅助或同步放化疗,所有患者均按期完成放化疗。中位随访时间为44月(6~87)月,其中44例出现复发或转移,39例患者死亡。患者的1、3、5年总生存率分别为92.3%、72.1%、56.8%,1、3、5年无进展生存率分别为82.4%、60.9%、53.3%。

    表  1  91例鼻咽癌患者临床基本特征资料(n(%))
    Table  1  Basic clinical features of 91 nasopharyngeal carcinoma patients (n(%))
    下载: 导出CSV 
    | 显示表格

    以OS作为终点,PLR、NLR为检测变量,绘制ROC曲线选取截断值分别为143.3、2.6,两者的曲线下面积分别为0.640、0.739,见图 1

    图  1  治疗前PLR、NLR与OS关系的ROC曲线图
    Figure  1  ROC curves of relationship between OS and PLR, NLR before treatment
    PLR: platelet-lymphocyte ratio; NLR: neutrophil-lymphocyte ratio

    以PFS作为终点,PLR、NLR为检测变量,绘制ROC曲线选取截断值分别为143.3、2.6,两者的曲线下面积分别为0.657、0.694,见图 2。说明治疗前PLR、NLR与患者的预后存在相关性,利用ROC曲线选取的截断值进行进一步生存分析。

    图  2  治疗前PLR、NLR与PFS关系的ROC曲线图
    Figure  2  ROC curves of relationship between PFS and PLR, NLR before treatment

    PLR≥143.3组和PLR < 143.3组患者生存曲线比较,差异有统计学意义(P=0.022),见图 3~4。NLR≥2.6组和NLR < 2.6组患者生存曲线比较,差异有统计学意义(P=0.044),见图 5~6

    图  3  治疗前PLR<143.3和PLR≥143.3组OS曲线的比较
    Figure  3  Comparison of OS between PLR < 143.3 and PLR≥143.3 groups before treatment
    OS: overall survival
    图  4  治疗前PLR<143.3组和PLR≥143.3组PFS曲线的比较
    Figure  4  Comparison of PFS between PLR < 143.3 and PLR≥143.3 groups before treatment
    PFS: progression-free survival
    图  5  治疗前NLR<2.6组和NLR≥2.6组OS曲线的比较
    Figure  5  Comparison of OS between NLR < 2.6 and NLR≥2.6 groups before treatment
    图  6  治疗前NLR<2.6组和NLR≥2.6组PFS曲线的比较
    Figure  6  Comparison of PFS between NLR < 2.6 and NLR≥2.6 groups before treatment

    Cox单因素分析显示除性别、年龄以外,TNM分期、治疗前PLR≥143.3、NLR≥2.6均是影响鼻咽癌患者OS和PFS的不良预后因素(P < 0.05),见表 2。Cox多因素分析显示治疗前PLR≥143.3(RR=2.491, 95%CI=1.139~5.451, P=0.022)、NLR≥2.6(RR=2.186, 95%CI=1.021~4.682,P=0.044)是鼻咽癌患者OS的独立危险因素,而治疗前PLR≥143.3(RR=2.461,95%CI=1.242~4.874, P=0.010)是鼻咽癌患者PFS的独立危险因素,见表 3

    表  2  影响鼻咽癌患者生存预后的Cox单因素分析
    Table  2  Cox univariate analysis of prognostic factors for nasopharyngeal carcinoma patients
    下载: 导出CSV 
    | 显示表格
    表  3  影响鼻咽癌患者生存预后的Cox多因素分析
    Table  3  Cox multivariate analysis of prognostic factors for nasopharyngeal carcinoma patients
    下载: 导出CSV 
    | 显示表格

    鼻咽癌对放射线高度敏感,因此放疗成为主要治疗手段。随着三维适形放疗和调强放射治疗的临床应用,鼻咽癌的生存率较前明显提高,但5年生存率仍仅为60%~80%。多项研究表明鼻咽癌患者预后与众多因素有关,包括患者年龄、临床分期、EB病毒感染及贫血等。此外,肿瘤的预后还与机体本身的炎性反应有关。炎性反应包含中性粒细胞、淋巴细胞、血小板、C反应蛋白等多种指标,其中PLR、NLR已受到越来越多专家的关注。本研究发现治疗前PLR和NLR可能成为鼻咽癌的独立预后因素。

    恶性肿瘤患者常伴随血小板的升高,实验研究表明血小板参与肿瘤细胞生长、转移及血管生成[16]。临床研究表明血小板数目升高与肿瘤患者较差预后相关[11, 17]。此外研究表明中性粒细胞可促使机体产生多种促肿瘤生长因子和蛋白酶,促进肿瘤的发生、发展[18]。而淋巴细胞参与机体的免疫反应是抗肿瘤免疫的重要组成部分,淋巴细胞减少说明机体免疫机制异常,抗肿瘤免疫力下降,为肿瘤生长、浸润和转移提供条件。随着肿瘤进展,机体内炎性反应与肿瘤失去平衡,体内淋巴细胞降低,而血小板、中性粒细胞升高,相应的PLR和NLR比值也增高,机体内促进肿瘤炎性反应与抗肿瘤炎性反应的平衡状态被打破。因此PLR和NLR是反应机体免疫情况的重要指标,两者的升高能促进肿瘤进展,导致肿瘤患者预后不良。既往研究结果显示高PLR和NLR可影响宫颈癌、乳腺癌、结直肠癌等恶性肿瘤的预后[19-21]。而目前关于PLR、NLR与鼻咽癌患者预后相关性的研究较少,Sun等[21]分析了251例鼻咽癌患者治疗前PLR和NLR,结果证明治疗前两者水平是影响鼻咽癌患者生存独立预后因素。本研究结果显示治疗前PLR、NLR与鼻咽癌患者的总生存期和无进展生存期具有相关性。Cox多因素分析提示PLR≥143.3、NLR≥2.6和TNM分期是影响鼻咽癌患者治疗后的独立危险因素。PLR≥143.3组患者有较短OS和PFS,而NLR≥2.6组患者有较差的OS,和本研究结果相一致。因此,高PLR、NLR的鼻咽癌患者总生存率要低于低PLR、NLR的患者,且高PLR的患者复发或转移风险明显增加。据此,临床上或许可以通过提高鼻咽癌患者免疫功能及降低机体炎性反应,改善患者的预后。

    但由于本研究是一个相对小样本的回顾性研究,不能代表大部分的鼻咽癌患者,且随访时间较短,存在一定的局限性,因此需要进行多中心、大样本的前瞻性研究来进一步证实。

    本研究结果表明,治疗前PLR和NLR水平与鼻咽癌患者预后具有相关性,可能是影响鼻咽癌患者预后的独立危险因素,NLR和PLR的获取具有简便、经济的优点,可以作为鼻咽癌患者病情评估的一个有益补充,值得推广。目前鼻咽癌相关有效预后指标较多,笔者将在今后的临床研究工作中继续探索,将本研究指标与已有的有效预后指标进行比较,从而提高治疗前PLR和NLR水平这一预后指标应用于临床的合理性及可靠性。

    Competing interests: The authors declare that they have no competing interests.
    利益冲突声明:
    所有作者均声明不存在利益冲突。
    作者贡献:
    李笑宇:资料收集、文章撰写
    张 楠:文章修改
    狄 文:指导及审阅文章
  • 表  1   近年来关于铂耐药性卵巢癌治疗的临床研究

    Table  1   Recent clinical studies on the treatment of platinum-resistant ovarian cancer

    Study Time Medication PFI Result
    McGuire WP, et al[16] 2009-2019 Olaratumab plus
    liposomal doxorubicin
    versus liposomal
    doxorubicin alone
    PFI<12 months PFS: 18.1(8.7-27.0) versus 17.3(14.1-31.9)
    OS: 72.3(52.4-86.7) versus 70.6(51.4-106.4)
    ORR: 12.9%(6.6-22.1) versus 16.4%(9.2-26.2)
    DOR: 39.1(26.1-56.1) versus 16.9(15.3-NA)
    Gaillard S, et al[17] 2015-2018 Lurbinectedin versus
    pegylated liposomal
    doxorubicin or
    topotecan
    PFI 1-6 months PFS: 3.5(2.1-3.7) versus 3.6(2.7-3.8)
    OS: 11.4(9.0-14.2) versus 10.9(9.3-12.5)
    ORR: 14.5%(10.1-19.8) versus 12.7%(8.6-17.8)
    DOR: 4.0(1.9-5.7) versus 3.7(3.6-7.2)
    McNeish IA, et al[18] 2010-2015 Saracatinib plus
    paclitaxel versus
    placebo plus
    paclitaxel
    PFI<6 months PFS: 29(22-37) versus 34(23-46)
    OS: 10.1(8.3-16.2) versus 12.3(11.0-14.4)
    ORR: 29 versus 43
    QoL: 66.9(1.89) versus 73.1(2.56)
    Liu JF, et al[19] 2011-2016 MM121 plus paclitaxel
    versus paclitaxel alone
    Platinum resistant
    or refractory
    PFS: 3.8(3.48-4.63) versus 3.7(2.56-5.52)
    OS: 13.7(8.77-NA) versus 10.1(8.77-NA)
    Pujade-Lauraine E,
    et al[20]
    2015-2019 Avelumab alone
    versus avelumab plus
    liposomal doxorubicin
    versus liposomal
    doxorubicin alone
    PFI<180 days OS: 11.8 (8.9-14.1) versus 15.7
    (12.7-18.7) versus 13.1 (11.8-15.5)
    PFS: 1.9 (1.8-1.9) versus 3.7
    (3.3-5.1) versus 3.5 (2.1-4.0)
    ORR: 3.7% (1.5-7.5) versus 13.3%
    (8.8-19.0) versus 4.2% (1.8-8.1)
    DOR: 9.2 (6.4-NA) versus 8.5
    (6.1-NA) versus 13.1 (5.5-NA)
    DCR: 33.0% (26.3-40.2) versus 57.4%
    (50.0-64.6) versus 48.9% (41.6-56.3)
    Pujade-Lauraine E,
    et al[21]
    2010-2014 Volasertib versus
    chemotherapy
    Platinum resistant
    or refractory
    DCR: 30.6% (18.0-43.2) versus 43.1% (29.5-56.7)
    PFS: 13.1 (6.6-30.1) versus 20.6 (11.6-30.7)
    OS: 60.1 (31.3-95.4) versus 68.6 (28.7-119.4)
    Pujade-Lauraine E,
    et al[14]
    2009-2015 Chemotherapy versus
    chemotherapy plus
    bevacizumab
    PFI<6 months PFS: 3.4 (2.10-3.75) versus 6.8 (5.62-7.79)
    ORR: 12.5% (7.1-17.9) versus 28.2% (20.8-35.6)
    DOR: 5.4 (3.81-9.23) versus 9.4 (6.60-11.63)
    OS: 9.4 (6.60-11.63) versus 16.6 (13.70-18.99)
    Lorusso D, et al[22] 2012-2016 Pertuzumab plus
    chemotherapy versus
    placebo plus
    chemotherapy
    Platinum resistant
    or refractory
    PFS: 4.3 (3.65-6.11) versus 2.7 (2.14-4.73)
    ORR: 14.8% (7.0-26.2) versus 8.7% (3.3-18.0)
    OS: 10.2 (6.67-15.24) versus 8.4 (6.14-11.99)
    Morre KN, et al[15] 2015-2020 Mirvetuximab
    soravtansine
    versus chemotherapy
    PFI<6 months PFS: 4.1 (3.75-4.53) versus 4.4 (2.83-5.59)
    ORR: 22 (17.2-27.9) versus 12 (6.6-19.1)
    OS: 15.6 (12.85-18.04) versus 13.9 (11.40-18.50)
    CA125 react: 51 (44.1-58.3) versus 27 (17.6-37.8)
    DOR: 5.7 (4.17-8.51) versus 7.3 (4.14-NA)
    下载: 导出CSV

    表  2   既往使用过其他治疗对复发时间及再次复发后治疗疗效的影响

    Table  2   Effect of previous use of other treatments on time to recurrence and efficacy of subsequent treatment after recurrence

    Study Previous treatment Treatment after recurrent Patient characteristic Result
    Cecere SC, et al[32] Olaparib after platinum-based chemotherapy Platinum-based chemotherapy PFI>12 months versus 6<PFI≤12 months versus PFI<6 months ORR: 22.2% versus 11.1% versus 9.5%
    Baert T, et al[33] Olaparib or no olaparib after platinum-based chemotherapy Platinum-based chemotherapy PARPi treatment before versus no PARPi treatment before DPR: 40% versus 9%
    Rose PG, et al[34] Olaparib or no olaparib after platinum-based chemotherapy Platinum-based chemotherapy PARPi treatment before versus no PARPi treatment before PFS: 8.0 versus 19.1 month (HR=4.01, 95%CI: 2.25-7.16, P<0.001)
    Frenel JS, et al[35] Olaparib or placebo after platinum-based chemotherapy Platinum- or non-platinum-based chemotherapy Placebo before versus olaparib before (All patients) TTSP: 12.1 versus 6.9 month (HR=2.17, 95%CI: 1.47-3.19)
    (Patients with platinum-based chemotherapy) TTSP: 14.3 versus 7.0 (HR=2.89, 95%CI: 1.73-4.82)
    Himoto Y, et al[36] New adjuvant chemotherapy / PDS versus NACT-IDS NACT-IDS is associated with shorter time to recurrence (P=0.017, HR=1.57)
    Ekmann-Gade AW,
    et al[37]
    New adjuvant chemotherapy / PDS versus NACT-IDS TFI: 372 days versus 497 days, P=0.042
    Luo Y, et al[38] New adjuvant chemotherapy / PDS versus NACT-IDS Number of platinum-resistant diseases: 99/283 (35%) versus 29/58 (50%, OR=2.950, P=0.001)
    Petrillo M, et al[39] New adjuvant chemotherapy / PDS versus NACT-IDS PFI: 13 versus 21; P=0.014 Proportion of platinum-resistant diseases: 35.9% versus 5.0%; P=0.006
    Note: TTSP: time to symptomatic progression.
    下载: 导出CSV
  • [1]

    Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. doi: 10.3322/caac.21834

    [2]

    Stewart C, Ralyea C, Lockwood S. Ovarian Cancer: An Integrated Review[J]. Semin Oncol Nurs, 2019, 35(2): 151-156. doi: 10.1016/j.soncn.2019.02.001

    [3]

    Wilson MK, Pujade-Lauraine E, Aoki D, et al. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease[J]. Ann Oncol, 2017, 28(4): 727-732. doi: 10.1093/annonc/mdw663

    [4]

    Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin[J]. J Clin Oncol, 1991, 9(3): 389-393. doi: 10.1200/JCO.1991.9.3.389

    [5]

    Friedlander M, Trimble E, Tinker A, et al. Clinical trials in recurrent ovarian cancer[J]. Int J Gynecol Cancer, 2011, 21(4): 771-775. doi: 10.1097/IGC.0b013e31821bb8aa

    [6]

    Armstrong DK, Alvarez RD, Bakkum-Gamez JN, et al. Ovarian Cancer, Version 2. 2020, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2021, 19(2): 191-226.

    [7]

    Havasi A, Cainap SS, Havasi AT, et al. Ovarian Cancer-Insights into Platinum Resistance and Overcoming It[J]. Medicina (Kaunas), 2023, 59(3): 544. doi: 10.3390/medicina59030544

    [8]

    Davis A, Tinker AV, Friedlander M. "Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit?[J]. Gynecol Oncol, 2014, 133(3): 624-631. doi: 10.1016/j.ygyno.2014.02.038

    [9]

    da Costa AABA, Dos Santos ES, Cotrim DP, et al. Prognostic impact of platinum sensitivity in ovarian carcinoma patients with brain metastasis[J]. BMC Cancer, 2019, 19(1): 1194. doi: 10.1186/s12885-019-6382-x

    [10]

    Baert T, Ferrero A, Sehouli J, et al. The systemic treatment of recurrent ovarian cancer revisited[J]. Ann Oncol, 2021, 32(6): 710-725. doi: 10.1016/j.annonc.2021.02.015

    [11]

    St Laurent J, Liu JF. Treatment Approaches for Platinum-Resistant Ovarian Cancer[J]. J Clin Oncol, 2024, 42(2): 127-133. doi: 10.1200/JCO.23.01771

    [12]

    Pejovic T, Fitch K, Mills G. Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”[J]. Cancer Drug Resist, 2022, 5(2): 451-458. doi: 10.20517/cdr.2021.138

    [13]

    Richardson DL, Eskander RN, O'Malley DM. Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review[J]. JAMA Oncol, 2023, 9(6): 851-859.

    [14]

    Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase Ⅲ trial[J]. J Clin Oncol, 2014, 32(13): 1302-1308.

    [15]

    Moore KN, Vergote I, Oaknin A, et al. FORWARD Ⅰ: a Phase Ⅲ study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer[J]. Future Oncol, 2018, 14(17): 1669-1678. doi: 10.2217/fon-2017-0646

    [16]

    McGuire WP, Penson RT, Gore M, et al. Randomized phase Ⅱ study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer[J]. BMC Cancer, 2018, 18(1): 1292. doi: 10.1186/s12885-018-5198-4

    [17]

    Gaillard S, Oaknin A, Ray-Coquard I, et al. Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)[J]. Gynecol Oncol, 2021, 163(2): 237-245. doi: 10.1016/j.ygyno.2021.08.032

    [18]

    McNeish IA, Ledermann JA, Webber L, et al. A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer[J]. Ann Oncol, 2014, 25(10): 1988-1995. doi: 10.1093/annonc/mdu363

    [19]

    Liu JF, Ray-Coquard I, Selle F, et al. Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer[J]. J Clin Oncol, 2016, 34(36): 4345-4353. doi: 10.1200/JCO.2016.67.1891

    [20]

    Pujade-Lauraine E, Fujiwara K, Dychter SS, et al. Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase Ⅲ study design[J]. Future Oncol, 2018, 14(21): 2103-2113. doi: 10.2217/fon-2018-0070

    [21]

    Pujade-Lauraine E, Selle F, Weber B, et al. Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase Ⅱ Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study[J]. J Clin Oncol, 2016, 34(7): 706-713. doi: 10.1200/JCO.2015.62.1474

    [22]

    Lorusso D, Hilpert F, González Martin A, et al. Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer[J]. Int J Gynecol Cancer, 2019, 29(7): 1141-1147. doi: 10.1136/ijgc-2019-000370

    [23]

    Champer M, Huang Y, Hou JY, et al. Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence[J]. Gynecol Oncol, 2018, 148(1): 19-27. doi: 10.1016/j.ygyno.2017.11.008

    [24]

    Lindemann K, Gao B, Mapagu C, et al. Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance[J]. Gynecol Oncol, 2018, 150(2): 239-246. doi: 10.1016/j.ygyno.2018.05.020

    [25]

    Tatsuki S, Shoji T, Abe M, et al. Efficacy and Safety of Platinum Rechallenge in Patients With Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: A Multicenter Retrospective Study[J]. Anticancer Res, 2022, 42(9): 4603-4610. doi: 10.21873/anticanres.15964

    [26]

    Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer[J]. N Engl J Med, 2019, 381(25): 2416-2428. doi: 10.1056/NEJMoa1911361

    [27]

    DiSilvestro P, Banerjee S, Colombo N, et al. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial[J]. J Clin Oncol, 2023, 41(3): 609-617. doi: 10.1200/JCO.22.01549

    [28]

    McMullen M, Karakasis K, Madariaga A, et al. Overcoming platinum and PARP-inhibitor resistance in ovarian cancer[J]. Cancers (Basel), 2020, 12(6): 1607. doi: 10.3390/cancers12061607

    [29]

    Park J, Kim SI, Jeong SY, et al. Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study[J]. Gynecol Oncol, 2022, 165(1): 97-104. doi: 10.1016/j.ygyno.2022.02.002

    [30]

    Liu J, Jiao X, Gao Q. Neoadjuvant chemotherapy-related platinum resistance in ovarian cancer[J]. Drug Discov Today, 2020, 25(7): 1232-1238. doi: 10.1016/j.drudis.2020.04.015

    [31]

    Lim MC, Song YJ, Seo SS, et al. Residual cancer stem cells after interval cytoreductive surgery following neoadjuvant chemotherapy could result in poor treatment outcomes for ovarian cancer[J]. Onkologie, 2010, 33(6): 324-330. doi: 10.1159/000313823

    [32]

    Cecere SC, Giannone G, Salutari V, et al. Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome[J]. Gynecol Oncol, 2020, 156(1): 38-44. doi: 10.1016/j.ygyno.2019.10.023

    [33]

    Baert T, Ataseven B, Bommert M, et al. 828P Expected observed response to platinum-based chemotherapy after poly (ADP-ribose) polymerase inhibitor treatment for relapsed ovarian cancer[J]. Ann Oncol, 2020, 31(Suppl 4): S624.

    [34]

    Rose PG, Yao M, Chambers LM, et al. PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer[J]. Anticancer Drugs, 2021, 32(10): 1086-1092. doi: 10.1097/CAD.0000000000001219

    [35]

    Frenel JS, Kim JW, Aryal N, et al. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial[J]. Ann Oncol, 2022, 33(10): 1021-1028. doi: 10.1016/j.annonc.2022.06.011

    [36]

    Himoto Y, Cybulska P, Shitano F, et al. Does the method of primary treatment affect the pattern of first recurrence in high-grade serous ovarian cancer?[J]. Gynecol Oncol, 2019, 155(2): 192-200. doi: 10.1016/j.ygyno.2019.08.011

    [37]

    Ekmann-Gade AW, Hogdall CK, Engelholm SA, et al. Neoadjuvant Chemotherapy Reduces the Treatment-free Interval After First-line Treatment in Patients With Advanced Ovarian Cancer[J]. Anticancer Res, 2020, 40(5): 2765-2770. doi: 10.21873/anticanres.14248

    [38]

    Luo Y, Lee M, Kim HS, et al. Effect of neoadjuvant chemotherapy on platinum resistance in stage ⅢC and Ⅳ epithelial ovarian cancer[J]. Medicine (Baltimore), 2016, 95(36): e4797. doi: 10.1097/MD.0000000000004797

    [39]

    Petrillo M, Ferrandina G, Fagotti A, et al. Timing and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapy[J]. Ann Surg Oncol, 2013, 20(12): 3955-3960. doi: 10.1245/s10434-013-3091-6

    [40]

    Colombo N, Sessa C, du Bois A, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease[J]. Ann Oncol, 2019, 30(5): 672-705. doi: 10.1093/annonc/mdz062

    [41]

    Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers[J]. JAMA, 2017, 317(23): 2402-2416. doi: 10.1001/jama.2017.7112

    [42]

    Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers[J]. Nat Rev Cancer, 2004, 4(10): 814-819. doi: 10.1038/nrc1457

    [43]

    Tan DS, Rothermundt C, Thomas K, et al. “BRCAness”syndrome in ovarian cancer: a case–control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations[J]. J Clin Oncol, 2008, 26(34): 5530-5536. doi: 10.1200/JCO.2008.16.1703

    [44]

    Bu H, Chen J, Li Q, et al. BRCA mutation frequency and clinical features of ovarian cancer patients: A report from a Chinese study group[J]. J Obstet Gynaecol Res, 2019, 45(11): 2267-2274. doi: 10.1111/jog.14090

    [45]

    Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group[J]. J Clin Oncol, 2012, 30(21): 2654-2663. doi: 10.1200/JCO.2011.39.8545

    [46]

    Gu P, Pan LL, Wu SQ, et al. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis[J]. Eur J Radiol, 2009, 71(1): 164-174. doi: 10.1016/j.ejrad.2008.02.019

    [47]

    Hall M, Rustin G. Recurrent ovarian cancer: when and how to treat[J]. Curr Oncol Rep, 2011, 13(6): 459-471. doi: 10.1007/s11912-011-0199-3

    [48]

    Rustin GJ, Nelstrop AE, Tuxen MK, et al. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study[J]. Ann Oncol, 1996, 7(4): 361-364. doi: 10.1093/oxfordjournals.annonc.a010602

    [49]

    Wilder JL, Pavlik E, Straughn JM, et al. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation[J]. Gynecol Oncol, 2003, 89(2): 233-235. doi: 10.1016/S0090-8258(03)00051-9

    [50]

    Lee CK, Simes RJ, Brown C, et al. A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer[J]. Ann Oncol, 2013, 24(4): 937-943. doi: 10.1093/annonc/mds538

    [51]

    Atallah GA, Kampan NC, Chew KT, et al. Predicting Prognosis and Platinum Resistance in Ovarian Cancer: Role of Immunohistochemistry Biomarkers[J]. Int J Mol Sci, 2023, 24(3): 1973. doi: 10.3390/ijms24031973

    [52]

    Pylväs-Eerola M, Liakka A, Puistola U, et al. Cancer Stem Cell Properties as Factors Predictive of Chemoresistance in Neoadjuvantly-treated Patients with Ovarian Cancer[J]. Anticancer Res, 2016, 36(7): 3425-3431.

    [53]

    Uno K, Yoshikawa N, Tazaki A, et al. Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy[J]. Sci Rep, 2022, 12(1): 4513. doi: 10.1038/s41598-022-08503-7

    [54]

    Patch AM, Christie EL, Etemadmoghadam D, et al. Whole-genome characterization of chemoresistant ovarian cancer[J]. Nature, 2015, 521(7553): 489-494. doi: 10.1038/nature14410

表(2)
计量
  • 文章访问数:  1471
  • HTML全文浏览量:  3665
  • PDF下载量:  887
  • 被引次数: 0
出版历程
  • 收稿日期:  2024-07-14
  • 修回日期:  2024-07-23
  • 录用日期:  2024-08-07
  • 网络出版日期:  2024-08-19
  • 刊出日期:  2024-10-24

目录

/

返回文章
返回
x 关闭 永久关闭